Potential Treatments Making Strides For Lilly
Lilly completed the CoLucid acquisition in March.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. (NYSE: LLY) says new studies on two potential lung cancer treatments are showing "encouraging" signs. The company presented data on early-phase trials on combinations of Alimta and Cyramza with Merck’s Keytruda at last week’s 52nd Annual Meeting of the American Society of Clinical Oncology.
The results involve patients with non-small cell lung cancer. Lilly Oncology Senior Vice President of Product Development And Medical Affairs Richard Gaynor says "these early data from the combinations of ALIMTA and KEYTRUDA in front-line nonsquamous NSCLC and CYRAMZA and KEYTRUDA in later lines of NSCLC are encouraging. We eagerly await Phase 2 and Phase 3 data with the ALIMTA and KEYTRUDA combinations and more mature data with the CYRAMZA and KEYTRUDA combination, in NSCLC, gastric and bladder cancers, to better understand the role of immuno-oncology combinations in improving patient outcomes in these settings." Gaynor also says the company is making progress on its research and development strategy, which involves three areas: tumor cell signaling, tumor microenvironment and immuno-oncology.
You can connect to more about the announcement by clicking here.